Meltendorf, StefanVogel, KatrinThurm, ChristophPrätsch, FlorianReinhold, AnnegretFärber, JacquelineHeuft, Hans-GertKaasch, Achim J.Hachenberg, ThomasWeinzierl, StefanSchraven, BurkhartReinhold, DirkBrunner-Weinzierl, Monika C.Lingel, Holger2022-12-232022-12-232022-10-220014-2980https://depositonce.tu-berlin.de/handle/11303/17877https://doi.org/10.14279/depositonce-16666After recovery, mild and severe COVID-19 diseases are associated with long-term effects on the host immune system, such as prolonged T-cell activation or accumulation of autoantibodies. In this study, we show that mild SARS-CoV-2 infections, but not SARS-CoV-2 spike mRNA vaccinations, cause durable atopic risk factors such as a systemic Th2- and Th17-type environment as well as activation of B cells responsive of IgE against aeroallergens from house dust mite and mold. At an average of 100 days post mild SARS-CoV-2 infections, anti-mold responses were associated with low IL-13 levels and increased pro-inflammatory IL-6 titers. Acutely severely ill COVID-19 patients instead showed no evidence of atopic reactions. Considering convalescents of mild COVID-19 courses and mRNA-vaccinated individuals together, IL-13 was the predominant significantly upregulated factor, likely shaping SARS-CoV-2 immunity. Application of multiple regression analysis revealed that the IL-13 levels of both groups were determined by the Th17-type cytokines IL-17A and IL-22. Taken together, these results implicate a critical role for IL-13 in the aftermath of SARS-CoV-2 mild infections and mRNA vaccinations, conferring protection against airway directed, atopic side reactions that occur in mildly experienced COVID-19.en610 Medizin und GesundheitallergyCOVID-19cytokinesSARS-CoV-2vaccinationArticle1521-4141